Myeloproliferative Neoplasms

Top Story

Leukemia & Lymphoma Society appoints board members, names chief operating officer

Leukemia & Lymphoma Society appoints board members, names chief operating officer
July 14, 2018
In the Journals Plus

American Cancer Society creates blueprint to reduce cancer mortality by 2035

July 10, 2018
Researchers from the American Cancer Society identified trends in disparities and outcomes for cancer over the last few decades in an effort to highlight the need for…

Luspatercept improves red blood cell transfusion independence in myelodysplastic syndrome

June 29, 2018
A randomized phase 3 trial designed to evaluate luspatercept among patients with myelodysplastic syndrome with chronic anemia met its primary endpoint, according to the…
Meeting NewsVideo

VIDEO: Takeda executive highlights research efforts in lung cancer, myeloma, myelodysplastic syndrome

June 19, 2018
CHICAGO — Stephen Noga, MD, PhD, vice president of U.S. medical affairs for Takeda Oncology, spoke with HemOnc Today at ASCO Annual Meeting about several trials…
More Headlines »
CME CPE CNE

Decisions, Decisions: Differentiating Checkpoint Inhibitors for Bladder Cancer

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Lung cancer is a leading cause of cancer death worldwide. The American Cancer Society estimates that there will be…
More »
Video

VIDEO: Toxicities related to immune therapies ‘unpredictable’ but ‘manageable’

June 23, 2016
More »
Resource Centers
ASCO Annual Meeting

ASCO Annual Meeting

CME CNE CPE

Immune Checkpoint Inhibitors for Genitourinary Cancers: Practice Essential for Community Oncologists and Advanced Practice Providers

This activity is supported by an educational grant from Merck & Co., Inc.

For many years, the mainstay of initial treatment for metastatic bladder cancer has been chemotherapy. However…
More »